



ANEXA 2

FIȘA DE VERIFICARE A ÎNDEPLINIRII STANDARDDELOR MINIMALE ÎN VEDEREA
OBTÎNERII ATESTATULUI DE ABILITARE ÎN CADRUL
I.O.S.U.D. U.M.F. "GRIGORE T POPA" DIN IAȘI

1. STANDARD MINIMAL ARTICOLE ISI AUTOR PRINCIPAL*

*calitatea de autor principal este atribuită pentru primul autor, ultimul autor, autorul corespondent, sau alți autori a căror contribuție este indicată explicit în cadrul publicației a fi egală cu contribuție primului autor sau a autorului corespondent

Domeniul Medicină, Farmacie: 10 articole, publicate pe parcursul întregii activități

Domeniul Medicină Dentară: 8 articole în reviste cu factor de impact >0.3, de la ultima promovare sau ultimii 5 ani (pentru candidații care provin din afara sistemului de învățământ)

RAPORTARE ARTICOLE ISI AUTOR PRINCIPAL

(listă, cu link-urile corespunzătoare pentru verificare, active)

1. Volovat SR, Ursulescu CL, Moisii LG, **Volovat C** (autor corespondent), Boboc D, Scripcariu D, Amurariti F, Stefanescu C, Stolniceanu CR, Agop M, Lungulescu C, Volovat CC. The Landscape of Nanovectors for Modulation in Cancer Immunotherapy. *Pharmaceutics*. 2022 Feb 11;14(2):397. doi: 10.3390/pharmaceutics14020397. PMID: 35214129; PMCID: PMC8875018. (IF: 5.4)
Link revistă: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8875018/pdf/pharmaceutics-14-00397.pdf>
Link dosar: [Articole ISI autor principal/pharmaceutics-14-00397 \(1\).pdf](#)
2. Volovat SR, Negru S, Stolniceanu CR, **Volovat C** (autor corespondent), Lungulescu C, Scripcariu D, Cobzeanu BM, Stefanescu C, Grigorescu C, Augustin I, Lupascu Ursulescu C, Volovat CC. Nanomedicine to modulate immunotherapy in cutaneous melanoma (Review). *Exp Ther Med*. 2021 May;21(5):535. doi: 10.3892/etm.2021.9967. Epub 2021 Mar 23. PMID: 33815608; PMCID: PMC8014970. (IF: 2.751)
Link revistă: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8014970/pdf/etm-21-05-09967.pdf>
Link dosar: [Articole ISI autor principal/etm 21_5_9967 PDF.pdf](#)
3. Ailincăi D, Agop M, Marinas IC, Zala A, Irimiciuc SA, Dobreci L, Petrescu TC, **Volovat C**. Theoretical model for the diclofenac release from PEGylated chitosan hydrogels. *Drug Deliv*. 2021 Dec;28(1):261-271. doi: 10.1080/10717544.2021.1876181. PMID: 33501878; PMCID: PMC7850333. (IF: 6.819)
Link revistă: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7850333/pdf/IDRD_28_1876181.pdf
Link dosar: [Articole ISI autor principal/Theoretical model for the diclofenac release from PEGylated chitosan hydrogels.pdf](#)
4. Săftescu S, Negru Ș, Volovăț S, Popovici D, Chercota V, Stanca S, Feier H, Malita D, Dragomir R, **Volovăț C**. Predictors of the response to nivolumab immunotherapy in the second or subsequent lines for metastatic non-small cell lung cancers. *Exp Ther Med*. 2021 Jun;21(6):605. doi: 10.3892/etm.2021.10037. Epub 2021 Apr 14. PMID: 33936262; PMCID: PMC8082661. (IF: 2.751)
Link revistă: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8082661/pdf/etm-21-06-10037.pdf>
Link dosar: [Articole ISI autor principal/etm 21_6_10037 PDF.pdf](#)
5. Volovat SR, Augustin I, Zob D, Boboc D, Amurariti F, **Volovat C** (autor corespondent), Stefanescu C, Stolniceanu CR, Ciocoiu M, Dumitras EA, Danciu M, Apostol DGC, Drug V, Shurbaji SA, Coca LG,

Leon F, Iftene A, Herghelegiu PC. Use of Personalized Biomarkers in Metastatic Colorectal Cancer and the Impact of AI. *Cancers (Basel)*. 2022 Oct 3;14(19):4834. doi: 10.3390/cancers14194834. PMID: 36230757; PMCID: PMC9562853. (IF: 5,2)

Link revistă: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9562853/pdf/cancers-14-04834.pdf>

Link dosar: <Articole ISI autor principal/cancers-14-04834.pdf>

6. Mireștean CC, **Volovăț C** (toți autorii cu contribuții egale), Iancu RI, Iancu DPT. Radiomics in Triple Negative Breast Cancer: New Horizons in an Aggressive Subtype of the Disease. *J Clin Med*. 2022 Jan 26;11(3):616. doi: 10.3390/jcm11030616. PMID: 35160069; PMCID: PMC8836903. (IF: 3,9)
Link revistă: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8836903/pdf/jcm-11-00616.pdf>
Link dosar: <Articole ISI autor principal/jcm-11-00616.pdf>
7. Volovat SR, **Volovat C** (autor corespondent), Hordila I, Hordila DA, Mireștean CC, Miron OT, Lungulescu C, Scripcariu DV, Stolniceanu CR, Konsoulova-Kirova AA, Grigorescu C, Stefanescu C, Volovat CC, Augustin I. MiRNA and LncRNA as Potential Biomarkers in Triple-Negative Breast Cancer: A Review. *Front Oncol*. 2020 Nov 20;10:526850. doi: 10.3389/fonc.2020.526850. PMID: 33330019; PMCID: PMC7716774. (IF: 6.244)
Link revistă: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7716774/pdf/fonc-10-526850.pdf>
Link dosar: <Articole ISI autor principal/fonc-10-526850.pdf>
8. **Volovat C**, Bondarenko I, Gladkov O, Buchner A, Lammerich A, Müller U, Bias P. Efficacy and safety of lipegfilgrastim compared with placebo in patients with non-small cell lung cancer receiving chemotherapy: post hoc analysis of elderly versus younger patients. *Support Care Cancer*. 2016 Dec;24(12):4913-4920. doi: 10.1007/s00520-016-3347-3. Epub 2016 Aug 8. PMID: 27501966. (IF: 2.698)
Link revistă: <https://link.springer.com/article/10.1007/s00520-016-3347-3>
Link dosar: <Articole ISI autor principal/s00520-016-3347-3.pdf>
9. **Volovat C**, Bondarenko IM, Gladkov OA, Elsässer R, Buchner A, Bias P, Müller U. Phase III, randomized, double-blind, placebo-controlled, multicenter study of lipegfilgrastim in patients with non-small cell lung cancer receiving myelosuppressive therapy. *Springerplus*. 2015 Jul 3;4:316. doi: 10.1186/s40064-015-1067-7. PMID: 26155455; PMCID: PMC4489970. (IF: 0.982)
Link revistă: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4489970/pdf/40064_2015_Article_1067.pdf
Link dosar: <Articole ISI autor principal/s40064-015-1067-7.pdf>
10. **Volovat C**, Gladkov OA, Bondarenko IM, Barash S, Buchner A, Bias P, Adar L, Avisar N. Efficacy and safety of balugrastim compared with pegfilgrastim in patients with breast cancer receiving chemotherapy. *Clin Breast Cancer*. 2014 Apr;14(2):101-8. doi: 10.1016/j.clbc.2013.10.001. Epub 2013 Oct 25. PMID: 24485296. (IF: 2.107)
Link revistă: [https://www.clinical-breast-cancer.com/article/S1526-8209\(13\)00238-3/fulltext](https://www.clinical-breast-cancer.com/article/S1526-8209(13)00238-3/fulltext)
Link dosar: <Articole ISI autor principal/volovat2014.pdf>
11. Volovat SR, **Volovat C** (autor cu contribuție egală cu primul autor), Miron I, Kanbay M, Goldsmith D, Lungulescu C, Badarau SC, Covic A. Oncogenic mechanisms in renal insufficiency. *Clin Kidney J*. 2020 Oct 23;14(2):507-515. doi: 10.1093/ckj/sfaa122. (IF: 4,5)
Link revistă: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7886561/pdf/sfaa122.pdf>
Link dosar: <Articole ISI autor principal/Oncogenic mechanisms.pdf>
12. Stolniceanu CR, Nistor I, Bilha SC, **Volovat C** (toți autorii cu contribuții egale), Simona V, Matovic M, Stefanescu C, Covic A. Nephrotoxicity/renal failure after therapy with 90Yttrium- and 177Lutetium-radiolabeled somatostatin analogs in different types of neuroendocrine tumors: a systematic review. *Nucl Med Commun*. 2020 Jul;41(7):601-617. doi: 10.1097/MNM.0000000000001198 (IF: 1,690)
Link revistă: https://journals.lww.com/nuclearmedicinecomm/abstract/2020/07000/nephrotoxicity_renal_failure_after_therapy_with.1.aspx
Link dosar: <Articole ISI autor principal/Nephrotoxicity:renal failure after therapy with 90Yttrium- and 177Lutetium.pdf>
13. Himiniuc LM, Toma BF, Popovici R, Grigore AM, Hamod A, **Volovat C** (toți autorii cu contribuții egale), Volovat S, Nica I, Vasincu D, Agop M, Tirnovanu M, Ochiuz L, Negura A, Grigore M. Update on the Use of Nanocarriers and Drug Delivery Systems and Future Directions in Cervical Cancer. *J*

Immunol Res. 2022 May 4;2022:1636908. doi: 10.1155/2022/1636908. (IF: 4,4)

Link revista: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9095399/pdf/JIR2022-1636908.pdf>

Lik dosar: <Articole ISI autor principal/1636908.pdf>

2. STANDARD MINIMAL ARTICOLE ISI COAUTOR

Domeniul Medicină, Farmacie: 5 articole, publicate pe parcursul întregii activități

RAPORTARE ARTICOLE ISI COAUTOR

(listă, cu link-urile corespunzătoare pentru verificare, active)

1. Tincu CEI, Popa M, Atanase LI, Popa O, Ochiuz L, Postolache P, Ghizdovat V, Irimiciuc SA, Agop M, **Volovat C**, Volovat S. Multi-fractal modeling of curcumin release mechanism from polymeric nanomicelles. Drug Deliv. 2022 Dec;29(1):2883-2896. doi: 10.1080/10717544.2022.2118402. PMID: 36062523; PMCID: PMC9448400. (IF: 6)
Link revistă: https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9448400/pdf/IDRD_29_2118402.pdf
Link dosar: <Articole ISI coautor/Multi fractal modeling of curcumin release mechanism from polymeric nanomicelles.pdf>
2. Ianole V, Danciu M, **Volovat C**, Stefanescu C, Herghelegiu PC, Leon F, Iftene A, Cusmulic CG, Toma B, Drug V, Ciobanu Apostol DG. Is High Expression of Claudin-7 in Advanced Colorectal Carcinoma Associated with a Poor Survival Rate? A Comparative Statistical and Artificial Intelligence Study. Cancers (Basel). 2022 Jun 13;14(12):2915. doi: 10.3390/cancers14122915. PMID: 35740581; PMCID: PMC9221359. (IF: 5.2)
Link revistă: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9221359/pdf/cancers-14-02915.pdf>
Link dosar: <Articole ISI coautor/cancers-14-02915-v2.pdf>
3. Stolniceanu CR, Moscalu M, Azoicai D, Tamba B, **Volovat C**, Grierosu I, Ionescu T, Jalloul W, Ghizdovat V, Gherasim R, Volovat S, Wang F, Fu J, Moscalu R, Matovic M, Stefanescu C. Improved Personalised Neuroendocrine Tumours' Diagnosis Predictive Power by New Receptor Somatostatin Image Processing Quantification. J Pers Med. 2021 Oct 17;11(10):1042. doi: 10.3390/jpm11101042. PMID: 34683183; PMCID: PMC8539645. (IF: 3.508)
Link revistă: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8539645/pdf/jpm-11-01042.pdf>
Link dosar: <Articole ISI coautor/jpm-11-01042.pdf>
4. Cobzeanu BM, Cobzeanu MD, Moscalu M, Palade OD, Rădulescu L, Negru D, Moisii LG, Cobzeanu LM, Ungureanu LB, Vonica P, Matei DV, Rusu DC, **Volovaț C**, Costan VV. Predictive Value of HPV, p53, and p16 in the Post-Treatment Evolution of Malignant Tumors of the Oropharynx and Retromolar Trigone-Oropharynx Junction. Medicina (Kaunas). 2020 Oct 15;56(10):542. doi: 10.3390/medicina56100542. PMID: 33076537; PMCID: PMC7602815. (IF: 2.43)
Link revistă: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7602815/pdf/medicina-56-00542.pdf>
Link dosar: <Articole ISI coautor/medicina-56-00542-v2.pdf>
5. Negru S, Papadopoulou E, Apeessos A, Stanculeanu DL, Ciuleanu E, **Volovat C**, Croitoru A, Kakolyris S, Aravantinos G, Ziras N, Athanasiadis E, Touroutoglou N, Pavlidis N, Kalofonos HP, Nasioulas G. KRAS, NRAS and BRAF mutations in Greek and Romanian patients with colorectal cancer: a cohort study. BMJ Open. 2014 May 23;4(5):e004652. doi: 10.1136/bmjopen-2013-004652. PMID: 24859998; PMCID: PMC4039802. (IF: 2.271)
Link revistă: <https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4039802/pdf/bmjopen-2013-004652.pdf>
Link dosar: <Articole ISI coautor/e004652.full.pdf>
6. Cobzeanu BM, Popescu E, Danciu M, Pașca AS, Palade OD, Vonica SP, Rădulescu LM, Ungureanu LB, Moscalu M, Cobzeanu ML, Gheorghe Moisii L, Cobzeanu MD, **Volovaț C**, Costan VV. Correlations between HPV, p53 and p16 in malignancies involving the retromolar trigone-oropharynx junction. Rom J Morphol Embryol. 2019;60(3):853-859. (IF: 1.411)
Link revista: <https://rjme.ro/RJME/resources/files/600319853859.pdf>
Link dosar: <Articole ISI coautor/COBZEANU.ROM.J.MORF.2020.pdf>
7. Lordick F, Kang YK, Chung HC, Salman P, Oh SC, Bodoky G, Kurteva G, Volovat C, Moiseyenko VM, Gorbunova V, Park JO, Sawaki A, Celik I, Götte H, Meležíňková H, Moehler M; Arbeitsgemeinschaft Internistische Onkologie and EXPAND Investigators (**Volovat C**). Capecitabine and cisplatin with or without cetuximab for patients with previously untreated advanced gastric cancer (EXPAND): a randomised, open-label phase 3 trial. Lancet Oncol. 2013 May;14(6):490-9. doi: 10.1016/S1470-2045(13)70102-5. (IF: 24.725)
Link revista: [https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045\(13\)70102-](https://www.thelancet.com/journals/lanonc/article/PIIS1470-2045(13)70102-)

[5/fulltext](#)

Link dosar: [Articole ISI coautor/Capecitabine and cisplatin with or without cetuximab.EXPAND.pdf](#)

8. Novello S, Scagliotti GV, Sydorenko O, Vynnychenko I, Volovat C, Schneider CP, Blackhall F, McCoy S, Hei YJ, Spigel DR. Motesanib plus carboplatin/paclitaxel in patients with advanced squamous non-small-cell lung cancer: results from the randomized controlled MONET1 study. J Thorac Oncol. 2014 Aug;9(8):1154-61. doi: 10.1097/JTO.0000000000000227. (IF: 5.282)

Link revista: [https://www.jto.org/article/S1556-0864\(15\)30646-8/fulltext](https://www.jto.org/article/S1556-0864(15)30646-8/fulltext)

Link dosar: [Articole ISI coautor/MOTESANIB.pdf](#)

3. STANDARD MINIMAL FACTOR CUMULAT DE IMPACT*

*se calculează ca sumă a factorilor de impact a revistelor în care au fost publicate articolele în calitate de autor principal, în anul apariției articolului

Domeniul Medicină, Farmacie: 10, pe parcursul întregii activități

Domeniul Medicină Dentară: 2,4, de la ultima promovare sau ultimii 5 ani (pentru candidații care provin din afara sistemului de învățământ)

RAPORTARE FACTOR CUMULAT DE IMPACT

(cifră, calculată conform indicațiilor, cu link-urile corespunzătoare pentru verificare, active)

[\(IF: 5,4\)+](#) [\(IF: 2.751\)+](#) [\(IF: 6.819\)+](#) [\(IF: 2.751\)+](#) [\(IF: 5,2\)+](#) [\(IF: 3,9\)+](#) [\(IF: 6.244\)+](#) [\(IF: 2.698\)+](#) [\(IF: 0.982\)+](#) [\(IF: 2.107\)+](#) [\(IF: 4,5\)+](#) [\(IF: 1,690\)+](#) [\(IF: 4,4\)=](#) 49,442

4. STANDARD MINIMAL INDICE HIRSCH*

Domeniul Medicină, Medicină Dentară, Farmacie = 6

*conform ISI Web of Science, Core Collection, Thomson Reuters

RAPORTARE INDICE HIRSCH

6

Link dosar: [Indice Hirsch/Screenshot 2023-09-03 at 23.57.55.png](#)

Link profil WoS: <https://www.webofscience.com/wos/author/record/523175>

5. STANDARD MINIMAL ARTICOLE BDI*

Domeniul Medicină Dentară: 20 articole de la ultima promovare, în calitate de autor principal

*echivalare = 1 articol ISI autor principal = 3 articole BDI autor principal, dar nu invers

RAPORTARE ARTICOLE BDI

(listă, cu link-urile corespunzătoare pentru verificare, active)

Nu se aplică.

Data,
04.04.2023

Șef lucrări dr. Volovăț Constantin

